Clinical development failure
Ategamosine is the lead asset, so adverse trial results would materially impair prospects.
- Scope
- THIO-101 to THIO-104 programs
- Materiality
- high
MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, with its lead molecule ateganosine (formerly THIO) at the center of its pipeline. The company is based in Chicago and operates through U.S. and international subsidiaries that support preclinical and clinical development activities.
1.66
1.66
| % | |
|---|---|
| Lead oncology candidate | 0% Ategamosine (THIO) and related clinical trial programs aimed at treating cancer. |
| Clinical development programs | 0% Ongoing human trials and supporting development work for the THIO platform. |
| Preclinical development | 0% Laboratory and early-stage work conducted through U.S., Australian, and Romanian operations. |
| Pipeline expansion | 0% Acquisition or in-licensing of additional product candidates to broaden the portfolio. |
MAIA does not currently sell commercial products; its primary “customers” are clinical investigators, trial sites, and...
- Clinical trial participantsprimary
Patients enrolled in oncology studies who receive ateganosine in MAIA-sponsored trials.
- Clinical investigators and trial sitesprimary
Hospitals, research centers, and investigators that execute the company’s clinical programs.
- Future oncology prescriberssecondary
Oncologists and healthcare systems that could adopt the drug if it reaches approval.
- Potential licensing partnerssecondary
Biopharma partners that may collaborate on development, commercialization, or asset in-licensing.
MAIA is headquartered in Chicago, Illinois, and its operations are primarily U.S.-based, with team members also working...
- •Headquartered in Chicago, Illinois
- •U.S. team members also work remotely in several states
- •Australian subsidiary supports preclinical and clinical work
- •Romanian subsidiary supports preclinical and clinical work
- •No disclosed revenue geography because the company has no revenue
MAIA’s strategy is centered on advancing ateganosine through clinical development while preserving flexibility to fund...
01
Advance ateganosine clinical developmentshort-term
The lead asset is the core value driver and the main path to future commercialization.
02
Secure additional financingshort-term
The company has no revenue and needs capital to fund trials and operations.
03
Broaden the pipelinemedium-term
Additional assets could reduce single-asset dependence and improve long-term optionality.
MAIA is a development-stage company with no revenue, so its business depends on successful clinical execution and...
Going-concern and liquidity risk
The company has no revenue, negative operating cash flow, and needs external financing to continue.
- Scope
- Cash runway and ability to fund trials
- Materiality
- high
Capital market dependence
Operations are funded through equity issuances and private placements, which may be dilutive.
- Scope
- ATM offerings, private placements, warrants
- Materiality
- high
Listing compliance risk
Failure to meet NYSE American requirements could trigger delisting and reduce trading liquidity.
- Scope
- Minimum stock price, equity, and public float tests
- Materiality
- medium
Geographic execution risk
Clinical and preclinical work spans the U.S., Australia, and Romania, increasing coordination complexity.
- Scope
- Multi-country development operations
- Materiality
- medium
Going-concern evaluation
Affects financial statement presentation and investor assessment of liquidity
Warrant liability fair value remeasurement
Can materially swing quarterly net loss
Stock-based compensation
Inflates reported G&A and net loss
Equity financing costs
Impacts cash runway and financing efficiency
ESTABLISHMENT LABS HOLDINGS INC.
ESTA · Orthopedic, Prosthetic & Surgical Appliances & Supplies
AIM ImmunoTech Inc.
AIM · Biological Products, (No Diagnostic Substances)
DYADIC INTERNATIONAL INC
DYAI · Biological Products, (No Diagnostic Substances)
Dyadic International is a U.S.-based biotechnology platform company that develops microbial protein production systems for industrial, life sciences, food and…
IO Biotech, Inc.
IOBTQ · Pharmaceutical Preparations
Stemtech Corp
STEK · Wholesale-Drugs, Proprietaries & Druggists' Sundries
Stemtech Corp develops and markets stem cell nutrition and personal care products, including dietary supplements, toothpaste, and skin-care items sold under proprietary brands.
SAIA INC
SAIA · Trucking (No Local)
: 28.4.2026